Addressing Systemic Racism in Biopharma

Addressing Systemic Racism in Biopharma

In 1997, as the new EVP responsible for research and development at Hoechst Marion Roussel (which later merged with RhonePoulenc Rorer to form Aventis, later acquired by Sanofi), I introduced a number of changes. [...]in addition to testing the rules and regulations for consistency with equity, they...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical Executive 2021-10, Vol.41 (10), p.50-50
1. Verfasser: Douglas, Frank L
Format: Artikel
Sprache:eng
Schlagworte:
Annual reports
Biotechnology industry
Clinical trials
Collaboration
Equity
Innovations
Kinases
Laboratories
Males
Multiculturalism & pluralism
Pandemics
Pharmaceutical industry
Product development
R&D
Research & development
Succession planning
Systemic racism
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In 1997, as the new EVP responsible for research and development at Hoechst Marion Roussel (which later merged with RhonePoulenc Rorer to form Aventis, later acquired by Sanofi), I introduced a number of changes. [...]in addition to testing the rules and regulations for consistency with equity, they should ask three questions: [...]old excuses such as "the pipeline of such individuals does not exist" should be buried in the dustbin of history.
ISSN:0279-6570
2150-735X